contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


oncozenge-receives-investment-capital-from-yangtian-bio-pharmaceutical

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

OncoZenge

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the ”Investor”).The ...

<div class="mfn-preamble"><p><strong>OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the ”Investor”).</strong></p></div><div class="mfn-body"><p>The investment made today by the investor amounts to SEK 9.1m.<br><br>On January 27, 2025, OncoZenge announced that the Company had entered into an investment agreement which provides the Investor with a maximum of 4&nbsp;669&nbsp;647 shares in the Company subject to an investment amounting to approximately SEK 30.2m. The purpose of the investment is to finance the Company’s Phase III project for BupiZenge™, targeting a European market approval.<br><br>The investment is to be executed by way of four directed new share issues equivalent to 10, 10, 30 and 50 percent of the total investment.<br><br>The two first investment tranches were received in July, 2025, and the third tranche in the amount of SEK 9.1m on February 12, 2026. This investment is consummated at the same price per share as in the two previous tranches, SEK 6,47 and will provide the investor with 1&nbsp;400&nbsp;894 new shares in the company.<br><br>The year-end report of the company will be published on February 26, 2026. The above investment will be reported as a pending new share issue as it was subscribed in December 2025.<br><br>Of note, the regulatory Outbound Direct Investment (“ODI”) process and approvals has been completed for the entirety of the investment agreement and will not need to be performed to release Tranche 4, expected in the second quarter of 2026 upon Clinical Trial Application approval by the EMA.</p></div><div class="mfn-footer mfn-c36bd55b4ec2"><p><strong class="mfn-heading-1">BupiZenge™ - Potential to be the leading treatment for oral pain.</strong><br> </p></div><div class="mfn-footer mfn-163a9926e483"><p><strong class="mfn-heading-1">Contacts</strong><br>Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.se<br>Michael Owens CFO Mobile: +46 73 324 4988 E-mail: michael.owens@oncozenge.se</p></div><div class="mfn-footer mfn-ba6514542f1c"><p><strong class="mfn-heading-1">About</strong><br>OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit <strong><a rel="noopener" href="http://www.oncozenge.se/">www.oncozenge.se</a></strong>.</p><p><strong>OncoZenge AB</strong><br>Gustavslundsvägen 34, 167 51 Stockholm, Sweden</p><p><strong>Certified Adviser</strong><br>OncoZenge's Certified Adviser is Redeye AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/e5d16291-d7ea-4952-b427-2342e439c832/oncozenge-receives-investment-capital-from-yangtian-bio-pharmaceutical.pdf" class="mfn-generated mfn-primary">OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical</a></p></div>